Torus Biosystems

Torus Biosystems was spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University in 2020 to develop and commercialize the proprietary DNA/RNA detection technology developed by Wyss Core Faculty member, Peng Yin, PhD, Professor, Department of Systems Biology, Harvard Medical School, and Wyss Alumnus David Zhang, PhD, Associate Professor of Bioengineering, Rice University. Learn more about how Torus Bio can help improve patient outcomes, combat antibiotic resistance, and promote antimicrobial stewardship in a wide range of ambulatory settings including Hospital Outpatient and Emergency Departments and Long-Term Care facilities. Visit the website at www.torus.bio and connect with on social media @Twitter and @LinkedIn.

Website

http://www.torus.bio

External link for Torus Biosystems

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Medford, Massachusetts

Type

Privately Held

Founded

2019

Specialties

syndromic testing, molecular diagnostics, infectious disease diagnostics, PCR, DNA, Nanotechnology, ambulatory care, hosptials, outpatient, emergency medicine, urgent care, long term care, geriatrics, point of care testing, POCT, multiplex, respiratory infections, Sars-CoV-2, syndromic panels, multiplex syndromic panels, and diagnostics